HOME ȸ»ç¼Ò°³ ½ÃÀÛÆäÀÌÁö·Î Áñ°Üã±âÃß°¡ ±âÀÚȸ¿ø½Åû
[¸ð¹ÙÀϸðµå] ·Î±×ÀΠȸ¿ø°¡ÀÔ
2024³â04¿ù26ÀÏfri
±â»çÃÖÁ¾ÆíÁýÀÏ: 2024-04-25 17:53:17
´º½ºÈ¨ > Á¦¾à
2016³â06¿ù20ÀÏ 12½Ã41ºÐ
±ÛÀÚÅ©±â ±â»ç³»¿ë À̸ÞÀϺ¸³»±â ´º½ºÇÁ¸°Æ®Çϱ⠴º½º½ºÅ©·¦Çϱâ
5ȸ ±¤µ¿ ¾ÏÇмú»ó '¹æ¿µÁÖ-¹Ú±ÙÄ¥-ÀÌ»ó¿í-¿ø¿µÁÖ' ¼ö»ó
17ÀÏ 'Á¦ 42Â÷ ´ëÇѾÏÇÐȸÇмú´ëȸ °â ±¹Á¦¾ÏÄÁÆÛ·±½º'¼­ »ó±Ý°ú »óÀå ¼ö¿©

¹æ¿µÁÖ ±³¼ö

¹Ú±ÙÄ¥ ±³¼ö

ÀÌ»ó¿í ±³¼ö

¿ø¿µÁÖ ¹Ú»ç

[º¸°ÇŸÀÓÁî] 'Á¦ 5ȸ ±¤µ¿ ¾ÏÇмú»ó'ÀÌ ¼­¿ï´ë ÀÇ´ë ³»°ú ¹æ¿µÁÖ ±³¼ö, »ï¼º¼­¿ïº´¿ø ³»°ú ¹Ú±ÙÄ¥ ±³¼ö, °¡Å縯°üµ¿´ë ¿¹¹æÀÇÇб³½Ç ÀÌ»ó¿í ±³¼ö, ±¹¸³¾Ï¼¾ÅÍ ¾Ïµî·Ï»ç¾÷°ú ¿ø¿µÁÖ ¹Ú»ç¿¡°Ô·Î µ¹¾Æ°¬´Ù.

±¤µ¿ ¾ÏÇмú»óÀº ±¤µ¿Á¦¾àÀÌ ´ëÇѾÏÇÐȸ¿Í °øµ¿ ½ÃÇàÇÏ´Â »óÀÌ´Ù.
ÀÌ »óÀº ´ëÇѾÏÇÐȸÁö¸¦ ÀοëÇØ ¿µÇâ·ÂÁö¼ö(Impact Factor, ÀÌÇÏ IF)°¡ ³ôÀº ¼öÁØÀÇ SCI ÇмúÁö¿¡ ÀÓ»ó³í¹®°ú ±âÃÊ³í¹®À» ¹ßÇ¥Çϰųª, ´Ù¼öÀÇ SCI Àú³Î¿¡ ¹ßÇ¥¸¦ ÇÏ´Â µî Ź¿ùÇÑ ¿¬±¸ ¼º°ú¸¦ ³½ ¿¬±¸ÀÚ¿¡°Ô ¼ö¿©ÇÑ´Ù.
ÃÖÁ¾ ¼ö»óÀÚ´Â ´ëÇѾÏÇÐȸ ÀÌ»çȸ ½É»ç¸¦ ÅëÇØ ¼±Á¤µÆ´Ù.

20ÀÏ ±¤µ¿Á¦¾à¿¡ µû¸£¸é ±¤µ¿ ¾ÏÇмú»ó ÀÓ»óÀÇÇкι®Àº ¼­¿ïÀÇ´ë ¹æ¿µÁÖ ±³¼ö¿Í »ï¼º¼­¿ïº´¿ø ¹Ú±ÙÄ¥ ±³¼ö°¡ J CLIN ONCOL(IF 18.428, 2014)¿¡ ³í¹® 'Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer', 'Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04'¸¦ °¢°¢ °ÔÀç, °øµ¿¼ö»óÇß´Ù.

¶Ç °¡Å縯°üµ¿´ë ÀÌ»ó¿í ±³¼ö´Â ±âÃÊÀÇÇкι®¿¡¼­ Int J Epidemiol(IF 9.176, 2014)¿¡ ³í¹® 'Sex-age-specific association of body mass index with all-cause mortality among 12.8 million Korean adults: a prospective cohort study'¸¦ °ÔÀç, ¿¬±¸ ¼º°ú¸¦ ÀÎÁ¤¹Þ¾Ò´Ù.
 
±¹¸³¾Ï¼¾ÅÍ ¿ø¿µÁÖ ¹Ú»ç´Â ´ëÇѾÏÇÐȸÁö¸¦ ÀοëÇØ ÃÑ 5ÆíÀÇ SCI Àú³Î¿¡ ³í¹®À» °ÔÀçÇÔÀ¸·Î½á ´ëÇѾÏÇÐȸÁö°¡ ±¹Á¦Àû À§»ó Á¤¸³¿¡ Å©°Ô ±â¿©Çß´Ù.

½Ã»ó½ÄÀº 17ÀÏ ¼­¿ï ¼Ò°øµ¿ ·Ôµ¥È£ÅÚ¿¡¼­ °³ÃÖµÈ 'Á¦ 42Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ °â ±¹Á¦¾ÏÄÁÆÛ·±½º’¿¡¼­ Ä¡·¯Á³À¸¸ç ºÎ¹®º°·Î 500¸¸¿øÀÇ »ó±Ý°ú »óÀåÀÌ ¼ö¿©µÆ´Ù.

±¤µ¿Á¦¾àÀº Áö³­ 2012³âºÎÅÍ ´ëÇѾÏÇÐȸ¿Í ±¤µ¿ ¾ÏÇмú»óÀ» Á¦Á¤, ¸Å³â ¼ö»óÀÚ¸¦ ¹ßÇ¥ÇÏ°í ÀÖ´Ù.
À̹ۿ¡ 2008³âºÎÅÍ ºñŸ¹ÎC ±¹Á¦½ÉÆ÷Áö¾öÀ» ÈÄ¿øÇÏ°í ÀÖÀ¸¸ç, ¿À´Â 22ÀÏ ºñ¸¸Ä¡·áÁ¦ ÄÜÆ®¶óºê ½ÉÆ÷Áö¾öÀ» °³ÃÖÇÏ´Â µî ´Ù¾çÇÑ Çмú Áö¿ø È°µ¿À» Áö¼ÓÇØ¿À°í ÀÖ´Ù.

 

°ü·Ã±â»ç°¡ ¾ø½À´Ï´Ù
´º½º½ºÅ©·¦Çϱâ
Á¶ÇöÁø (bktimes@naver.com) ±âÀÚ 
À̱âÀÚÀÇ ´Ù¸¥´º½ºº¸±â
Á¦¾à¼½¼Ç ¸ñ·ÏÀ¸·Î
Æĸã½Å, Ú¸ AACR 2021¼­ 'P...
Å»¸®´ÙÄñ, ±¹°¡´ëÇ¥ Ź±¸ ...
½ÅdzÁ¦¾à Äڷγª19 Ä¡·áÁ¦ ...
µ¿¾ÆÁ¦¾à, ºñ¿¡½ºÆ¼¿Í È­Àå...
À¯³ªÀÌƼµå¹®È­Àç´Ü, È÷½º...
´ÙÀ½±â»ç : ¸Þµðµ¥ÀÌÅÍ-GSK mHealth '¿ÃÇØ ÀÓ»ó ÆÄÆ®³Ê ½Ê' ¼ö»ó (2016-06-20 15:32:00)
ÀÌÀü±â»ç : Á¾±Ù´ç ¡®µàºñ¿¡¡¯, Á¦2Çü ´ç´¢º´ ȯÀÚ Áö¹æ°£ °³¼± (2016-06-20 10:48:50)
º´¿ø°è, "°è...
º´¿ø°è, "°è¹¦³â...
Á¦¾à¡¤°Ç½Ä 12°³...
°Çº¸°ø´Ü, ¼Ò¼Ó±â°ü '¼­¿ï¿ä¾ç...
¼ºÀåÇÏ°íÇ ´ç½Å, "Áö±Ý ´ë¿õ,...
º¸·ÉÁ¦¾à, ¿Ã »ó¹Ý±â '¿µ¾÷Á÷ ...
°Çº¸°ø´Ü, ¿ÃÇØ '°³¹æÇü Á÷°ú ...
°Çº¸°ø´Ü, '¿Ã Á¦3Â÷ °³¹æÇü ...
³í¹®) Visual Impairment and Suicide Risk...  
ȸ»ç¼Ò°³ °³ÀÎÁ¤º¸º¸È£Á¤Ã¥ ÀÌ¿ë¾à°ü À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ ¾Ë¸³´Ï´Ù º¸µµÀÚ·á ±â»çÁ¦º¸ Á¤±â±¸µ¶